Portfolio - Therapeutics
Investing in the miracle of biologics
Covagen is developing next generation biologic fynomers to fight inflammatory diseases and cancer. The lead programme is an antibody-fynomer bispecific molecule targeting IL17 and TNF cytokines. The second programme is a bispecific antibody-fynomer targeting Her-2 to treat breast cancer.
Background: Antibodies have become the blockbuster therapies of the 21stcentury. The race is now on to develop next generation biologics; with ease of manufacture, enhanced cell-killing abilities and multivalent molecules capable of binding several targets simultaneously. Covagen’s fynomer technology is uniquely positioned to address these challenges.
Our Involvement: We had tracked the evolution of the antibody field over many years. We believed there to be an opportunity for low molecular weight alternatives with the specificity of antibodies but increased flexibility to mix-and-match domains to create unique and superior biologics. We led a Series A financing into Covagen, where we hold a Board seat and play an active role inthe company’s strategy, business development, financing and recruitment.
Market Need: Rheumatoid arthritis (RA) affects about 1% of the US population and is a serious and potentially disabling autoimmune disease. TNF inhibitors for the treatment of RA had over $22 billion in sales in 2010 and Covagen’s lead product will be targeting this market. The second programme targets Her-2positive breast cancer patients, also a multi-billion dollar market opportunity.
Status: Lead molecule targeting IL17 and TNF cytokines in advanced preclinical development.more
Seroba Kernel Contact: Jonathan Hepple